U.S. Markets close in 5 hrs 8 mins

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.07-0.34 (-1.85%)
As of 10:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.41
Open17.35
Bid18.18 x 1200
Ask18.24 x 800
Day's Range18.05 - 18.43
52 Week Range9.01 - 21.30
Volume33,601
Avg. Volume712,815
Market Cap847.792M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-3.99
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.25
  • Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
    Business Wire

    Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

  • Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
    Business Wire

    Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled, "Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis." This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa® (netarsudil ophthalmic solution) 0.02% in the United States, on steroid-induced ocular hypertension in a mouse model and steroid-induced glaucoma in humans.

  • Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?
    Zacks

    Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.